BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28980517)

  • 41. Short-Course Versus Long-Course Chemoradiotherapy for Stage IE-IIE Extranodal Natural Killer/T cell Lymphoma, Nasal Type: A Multicenter Retrospective Study.
    Li J; Li Y; Zhong M; Liu X; Song Y; Li J; Li K; Yi P
    Med Sci Monit; 2018 May; 24():2683-2692. PubMed ID: 29712887
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
    Oh D; Ahn YC; Kim SJ; Kim WS; Ko YH
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):677-83. PubMed ID: 26461010
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma.
    Moon JH; Lee BH; Kim JA; Lee YJ; Chae YS; Yhim HY; Kwak JY; Do YR; Park Y; Song MK; Shin HJ; Kim T; Lee JJ; Yang DH
    Leuk Res; 2016 Oct; 49():80-7. PubMed ID: 27608179
    [TBL] [Abstract][Full Text] [Related]  

  • 44. "Sandwich" Chemotherapy (CT) with Radiotherapy (RT) improves outcomes in patients with stage IE/IIE extranodal natural killer (NK)/T-cell Lymphomas.
    Zhang J; Zhu MY; Wang L; Wang H; Wang WD; Geng QR; Lu Y
    Asian Pac J Cancer Prev; 2013; 14(7):4061-6. PubMed ID: 23991953
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study.
    Yang Y; Zhu Y; Cao JZ; Zhang YJ; Xu LM; Yuan ZY; Wu JX; Wang W; Wu T; Lu B; Zhu SY; Qian LT; Zhang FQ; Hou XR; Li YX
    Blood; 2015 Sep; 126(12):1424-32; quiz 1517. PubMed ID: 26109206
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma.
    Niu SQ; Yang Y; Li YY; Wen G; Wang L; Li ZM; Wang HY; Zhang LL; Xia YF; Zhang YJ
    Chin J Cancer; 2016 Apr; 35():34. PubMed ID: 27044275
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diagnosis and management of extranodal NK/T cell lymphoma nasal type.
    Tse E; Kwong YL
    Expert Rev Hematol; 2016 Sep; 9(9):861-71. PubMed ID: 27347812
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan.
    Yamaguchi M; Suzuki R; Oguchi M; Asano N; Amaki J; Akiba T; Maeda T; Itasaka S; Kubota N; Saito Y; Kobayashi Y; Itami J; Ueda K; Miyazaki K; Ii N; Tomita N; Sekiguchi N; Takizawa J; Saito B; Murayama T; Ando T; Wada H; Hyo R; Ejima Y; Hasegawa M; Katayama N
    J Clin Oncol; 2017 Jan; 35(1):32-39. PubMed ID: 28034070
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type.
    Huang Y; Yang J; Liu P; Zhou S; Gui L; He X; Qin Y; Zhang C; Yang S; Xing P; Sun Y; Shi Y
    Ann Hematol; 2017 Sep; 96(9):1477-1483. PubMed ID: 28695246
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.
    Kim SJ; Choi JY; Hyun SH; Ki CS; Oh D; Ahn YC; Ko YH; Choi S; Jung SH; Khong PL; Tang T; Yan X; Lim ST; Kwong YL; Kim WS;
    Lancet Haematol; 2015 Feb; 2(2):e66-74. PubMed ID: 26687611
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nasal endoscopic evaluation and its impact on survival in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type.
    Cho HJ; Jang MS; Hong SD; Kim SJ; Ahn YC; Oh D; Ko YH; Kim HY; Dhong HJ; Chung SK; Kim WS
    Int Forum Allergy Rhinol; 2015 Oct; 5(10):960-6. PubMed ID: 26039707
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma.
    Dong LH; Zhang LJ; Wang WJ; Lei W; Sun X; Du JW; Gao X; Li GP; Li YF
    Leuk Lymphoma; 2016 Jul; 57(7):1600-6. PubMed ID: 26726970
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy.
    Yamaguchi M; Suzuki R; Kim SJ; Ko YH; Oguchi M; Asano N; Miyazaki K; Terui Y; Kubota N; Maeda T; Kobayashi Y; Amaki J; Soejima T; Saito B; Shimoda E; Fukuhara N; Tsukamoto N; Shimada K; Choi I; Utsumi T; Ejima Y; Kim WS; Katayama N
    Cancer Sci; 2018 Jun; 109(6):2056-2062. PubMed ID: 29601137
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma.
    Huang Y; Jia B; Jiang S; Zhou S; Yang J; Liu P; Gui L; He X; Qin Y; Sun Y; Shi Y
    J Hematol Oncol; 2017 Jan; 10(1):7. PubMed ID: 28057019
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer.
    Lester-Coll NH; Young MR; Park HS; Ratner ES; Litkouhi B; Damast S
    Int J Gynecol Cancer; 2017 Nov; 27(9):1904-1911. PubMed ID: 28763364
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A clinical study of 115 patients with extranodal natural killer/T-cell lymphoma, nasal type.
    Wu X; Li P; Zhao J; Yang X; Wang F; Yang YQ; Fang F; Xu Y; Zhang H; Wang WY; Yi C
    Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):619-25. PubMed ID: 18790372
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group.
    Wu T; Yang Y; Zhu SY; Shi M; Su H; Wang Y; He X; Xu LM; Yuan ZY; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Zhang YJ; Zhu Y; Cao JZ; Lan SM; Wu JX; Hu C; Qi SN; Chen B; Li YX
    Blood Adv; 2018 Sep; 2(18):2369-2377. PubMed ID: 30242098
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment outcomes and prognostic analysis of elderly patients with extranodal natural killer/T-cell lymphoma, nasal type: a retrospective analysis.
    Wei L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Cui X; Wu Y; Ding J; Wang J
    Leuk Lymphoma; 2020 Dec; 61(12):2962-2968. PubMed ID: 32686544
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Extranodal natural killer/T-Cell lymphoma: A population-based comparison of sinonasal and extranasal disease.
    Vazquez A; Khan MN; Blake DM; Sanghvi S; Baredes S; Eloy JA
    Laryngoscope; 2014 Apr; 124(4):888-95. PubMed ID: 24114591
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study.
    Qi SN; Yang Y; Zhang YJ; Huang HQ; Wang Y; He X; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Qiao XY; Wang H; Li GF; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Xu LM; Yuan ZY; Su H; Song YQ; Zhu J; Hu C; Li YX
    Am J Hematol; 2020 Sep; 95(9):1047-1056. PubMed ID: 32449800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.